Sarepta Therapeutics (SRPT) Other Non Operating Income (2010 - 2026)
Sarepta Therapeutics' quarterly Other Non Operating Income came in at -$15.3 million in Q1 2026, up 81.64% year-on-year from -$8.4 million in Q1 2025, and up 90.34% quarter-over-quarter from -$157.9 million in Q4 2025.
Sarepta Therapeutics has reported Other Non Operating Income for 17 years, with the latest figure at -$15.3 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 81.64% year-over-year to -$15.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 103.9% YoY), and the FY2025 full-year result was -$19.3 million, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$15.3 million, up from -$157.9 million in the prior quarter.
- The five-year high for Other Non Operating Income was $387.3 million in Q1 2023, with the low at -$404.6 million in Q4 2023.
- Average Other Non Operating Income over 5 years is $138727.3, with a median of $6.5 million recorded in 2024.
- Peak annual rise in Other Non Operating Income reached 765.67% in 2025, while the deepest fall reached 1370.55% in 2025.
- Tracing SRPT's Other Non Operating Income over 5 years: stood at $98.5 million in 2022, then slumped by 510.8% to -$404.6 million in 2023, then surged by 94.85% to -$20.8 million in 2024, then tumbled by 658.4% to -$157.9 million in 2025, then jumped by 90.34% to -$15.3 million in 2026.
- The last three Other Non Operating Income figures came in at -$15.3 million (Q1 2026), -$157.9 million (Q4 2025), and $138.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.26 Mn |
| Dec 31, 2025 | -157.91 Mn |
| Sep 30, 2025 | 138.60 Mn |
| Jun 30, 2025 | 38.06 Mn |
| Mar 31, 2025 | -83.13 Mn |
| Sep 30, 2024 | -20.82 Mn |
| Jun 30, 2024 | 14.28 Mn |
| Mar 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | -404.64 Mn |
| Mar 31, 2023 | 387.30 Mn |
| Sep 30, 2022 | 98.50 Mn |
| Dec 31, 2021 | -60.58 Mn |
| Jun 30, 2021 | -406,000.00 |
| Mar 31, 2021 | 64,000.00 |
| Dec 31, 2020 | 160,000.00 |
| Sep 30, 2020 | -881,000.00 |
| Jun 30, 2020 | -371,000.00 |
| Mar 31, 2020 | 1.09 Mn |
| Dec 31, 2019 | -211,000.00 |
| Sep 30, 2019 | -374,000.00 |
| Jun 30, 2019 | -121,000.00 |
| Mar 31, 2019 | 470,000.00 |
| Dec 31, 2018 | -86,000.00 |
| Sep 30, 2018 | -59,000.00 |
| Jun 30, 2018 | -529,000.00 |
| Mar 31, 2018 | 18,000.00 |
| Dec 31, 2017 | -2.69 Mn |
| Sep 30, 2017 | 115,000.00 |
| Jun 30, 2017 | 100,000.00 |
| Mar 31, 2017 | 335,000.00 |
| Dec 31, 2016 | -57,000.00 |
| Sep 30, 2016 | -209,000.00 |
| Jun 30, 2016 | -201,000.00 |
| Mar 31, 2016 | -68,000.00 |
| Dec 31, 2015 | -229,000.00 |
| Sep 30, 2015 | -176,000.00 |
| Jun 30, 2015 | 256,000.00 |
| Mar 31, 2015 | 303,000.00 |
| Dec 31, 2014 | 306,000.00 |
| Sep 30, 2014 | 193,000.00 |
| Jun 30, 2014 | 181,000.00 |
| Mar 31, 2014 | 99,000.00 |
| Dec 31, 2013 | 45,000.00 |
| Sep 30, 2013 | 63,000.00 |
| Jun 30, 2013 | -19,000.00 |
| Mar 31, 2013 | 237,000.00 |
| Dec 31, 2012 | 83,000.00 |
| Sep 30, 2012 | 67,000.00 |
| Jun 30, 2012 | 107,000.00 |
| Mar 31, 2012 | 96,000.00 |
| Dec 31, 2011 | 7.44 Mn |
| Sep 30, 2011 | 7.05 Mn |
| Jun 30, 2011 | 11.25 Mn |
| Mar 31, 2011 | 7.27 Mn |
| Dec 31, 2010 | -5.99 Mn |
| Sep 30, 2010 | -3.58 Mn |
| Jun 30, 2010 | -9.04 Mn |